Targeting the Brain 5-HT7 Receptor to Prevent Hypomyelination in a Rodent Model of Perinatal White Matter Injuries
Overview
Authors
Affiliations
Approximately 15 million babies are born prematurely every year and many will face lifetime motor and/or cognitive deficits. Children born prematurely are at higher risk of developing perinatal brain lesions, especially white matter injuries (WMI). Evidence in humans and rodents demonstrates that systemic inflammation-induced neuroinflammation, including microglial and astrocyte reactivity, is the prominent processes of WMI associated with preterm birth. Thus, a new challenge in the field of perinatal brain injuries is to develop new neuroprotective strategies to target neuroinflammation to prevent WMI. Serotonin (5-HT) and its receptors play an important role in inflammation, and emerging evidence indicates that 5-HT may regulate brain inflammation by the modulation of microglial reactivity and astrocyte functions. The present study is based on a mouse model of WMI induced by intraperitoneal (i.p.) injections of IL-1β during the first 5 days of life. In this model, certain key lesions of preterm brain injuries can be summarized by (i) systemic inflammation, (ii) pro-inflammatory microglial and astrocyte activation, and (iii) inhibition of oligodendrocyte maturation, leading to hypomyelination. We demonstrate that Htr7 mRNA (coding for the HTR7/5-HT7 receptor) is significantly overexpressed in the anterior cortex of IL-1β-exposed animals, suggesting it as a potential therapeutic target. LP-211 is a specific high-affinity HTR7 agonist that crosses the blood-brain barrier (BBB). When co-injected with IL-1β, LP-211 treatment prevented glial reactivity, the down-regulation of myelin-associated proteins, and the apparition of anxiety-like phenotypes. Thus, HTR7 may represent an innovative therapeutic target to protect the developing brain from preterm brain injuries.
The Importance of Stereochemistry in 5-HTR Modulation─A Case Study of Hydantoin Derivatives.
Kucwaj-Brysz K, Bas S, Zeslawska E, Podlewska S, Jastrzebska-Wiesek M, Partyka A ACS Chem Neurosci. 2024; 15(21):3884-3900.
PMID: 39433990 PMC: 11587507. DOI: 10.1021/acschemneuro.4c00152.
Fischer I, Shohat S, Leichtmann-Bardoogo Y, Nayak R, Wiener G, Rosh I Sci Adv. 2024; 10(41):eadl4573.
PMID: 39392881 PMC: 11468907. DOI: 10.1126/sciadv.adl4573.
Xue D, Guo X, Liu J, Li Y, Liu L, Liao G J Neuroinflammation. 2024; 21(1):241.
PMID: 39334486 PMC: 11437714. DOI: 10.1186/s12974-024-03239-9.
Zhang P, Gao C, Guo Q, Yang D, Zhang G, Lu H J Neuroinflammation. 2024; 21(1):140.
PMID: 38807233 PMC: 11131315. DOI: 10.1186/s12974-024-03113-8.